Anti-GD2 Antibody Engineering for Reduced Neuropathic Pain
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-GD2 antibody therapies for neuroblastoma and other cancers are limited by severe neuropathic pain and peripheral neuropathy due to complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC) effector functions.
Innovation Solution
Development of a humanized anti-GD2 antibody, hu14.18-IgG1.4 (K322A)-delK, engineered to reduce or eliminate CDC and ADCC effector functions, conjugated with a non-neurotoxic cytotoxic payload, Exatecan, to selectively deliver the payload to malignant cells while minimizing toxicity to normal tissues.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If anti-GD2 antibody therapies are used to treat neuroblastoma, then tumor cell killing activity is improved, but severe neuropathic pain and peripheral neuropathy occur due to CDC and ADCC effector functions
Solution Approach 1:
The patent extracts and removes the harmful effector functions (CDC and ADCC) from the anti-GD2 antibody by engineering mutations in the Fc region (e.g., L234A/L235A double mutation) that abolish complement binding and Fcγ receptor binding, while preserving the antigen-binding capability of the antibody variable regions
Solution Approach 2:
The patent applies local quality modification by introducing specific point mutations only in the Fc region of the antibody (constant domains) while leaving the Fab regions (antigen-binding domains) unchanged, thereby locally altering the effector function properties without affecting target recognition
2Reliability
If conventional anti-GD2 antibodies are used, then immunotherapy efficacy is improved, but dose is limited by severe toxicities including neuropathic pain
Solution Approach 1:
The patent converts the harmful effector functions into a beneficial absence by engineering antibodies that lack CDC and ADCC activity, thereby eliminating the harmful side effects while maintaining the therapeutic benefit through alternative mechanisms such as antibody-dependent cellular phagocytosis (ADCP) or direct tumor cell recognition
Solution Approach 2:
The patent changes the biochemical parameters of the antibody by introducing specific amino acid substitutions (e.g., L234A/L235A, N297A) in the Fc region that fundamentally alter the antibody's interaction with immune effector cells and complement system, thereby changing the mechanism of action from cytotoxic to non-cytotoxic
3Stability of the object's composition
If enzyme-cleavable linkers are used to conjugate cytotoxic agents, then serum stability is improved, but hydrophobicity increases leading to ADC aggregation
Solution Approach 1:
The patent uses composite linker design combining hydrophilic moieties (such as PEG chains or charged amino acid sequences) with enzyme-cleavable segments, creating a composite structure that provides both serum stability through the hydrophilic portion and controlled cleavage through the enzyme-sensitive segment, while reducing overall hydrophobicity
Solution Approach 2:
The patent applies local quality modification to the linker by incorporating hydrophilic character at specific positions (such as N-terminal or C-terminal ends of the linker) while maintaining the enzyme-cleavable core sequence, thereby locally reducing hydrophobicity without compromising the overall stability function
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The engineered anti-GD2 ADC achieves a broader therapeutic window, reducing neuropathic pain and peripheral neuropathy, while maintaining effective tumor cell killing, thus improving treatment outcomes for patients with GD2-expressing tumors.
Implementation Method 1
anti-GD2 antibodies... which bind human GD2 (Disialoganglioside GD2)
Implementation Method 2
Enzyme-cleavable linkers utilize the differential activities of proteases inside and outside of the cells to achieve control of the drug release
Data Source
AI summary
The invention provides antibodies which bind human GD2 protein, as well as isolated nucleic acids and host cells comprising a sequence encoding said antibodies. The invention also provides immunoconjugates comprising said antibodies linked to a growth-inhibitory agent, and pharmaceutical compositions comprising antibodies or immunoconjugates of the invention. The invention also provides use of the antibodies, immunoconjugates and pharmaceutical compositions of the invention for the treatment of cancer or for diagnostic purposes.